VEGFA and endothelial dysfunction: Furthermore, the clinically available Bevacizumab (an anti-vascular endothelial growth factor, VEGF, antibody) [119] and multi-targeted tyrosine kinase inhibitors (TKIs, target the VEGF receptor), such as Sorafenib and Sunitinib [120], cause endothelial dysfunction and capillary rarefaction [6,7,117].